-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: February 2013
Celgene CEO on New Multiple Myeloma Drug Approvals
Following on the heels of two big announcements in February, Celgene CEO Robert Hugin (one of FierceBiotech’s most influential people in biopharma) participated in a fireside chat with Joel Sendek, managing director and biotechnology analyst at Stifel Nicolaus & Company, at the 15th Annual BIO CEO & Investor Conference in New York. First, on Friday, February 8, the Food and Drug Administration (FDA) approved Celgene’s drug Pomalyst for patients with multiple myeloma whose disease has Read More >
STEM Education Aimed at Girls
We write a fair bit about STEM education here at BIOtechNOW, so I was a bit surprised to come across a word I’d never heard before. STEMinists may be a made-up word, but it’s still a good one. In case you haven’t figured it out yet, let me help you: STEM + feminists = STEMinists. In other words, it’s a young women who’s interested in science, technology, engineering and math (STEM) fields. As the father Read More >
Biotech Hall of Fame: Interview with Biotech’s First Investment Banker
Earlier this week, I had the opportunity to discuss biotech’s storied history with Fred Frank, one of the industry’s greatest luminaries, on what we can learn from the past to help shape the future. Fred Frank, formerly Vice Chairman of both Lehman Brothers Inc. and Peter J. Solomon Company, recently became Vice Chairman of Burrill & Company and Chairman of Burrill Securities, the broker dealer arm of Burrill & Company. He was the first life Read More >
Brazil Patent Policy: At a Crossroads
The Government of Brazil approaches the patent policy crossroads with two ministries wanting to move in opposite directions. In the last few months, both the Brazilian Patent Office (INPI) and the Brazilian Regulatory Authority (ANVISA) issued proposed rules concerning patents and are sifting through public comments to determine how they will deal with biotech patents. A quirk in Brazilian law requires that the health regulatory authority (ANVISA) must provide “prior consent” on the grant of a pharmaceutical patent. Traditionally, Read More >
A Call to Arms for Renewable Fuels
BIO President & CEO Jim Greenwood delivered remarks on the Renewable Fuel Standard and participated in a panel session on the Legacy of Bipartisan Support for Renewable Energy at ACORE’s National Renewable Energy Policy Forum, held on Capitol Hill: Good afternoon. It is good to be with ACORE again and to be part of your 10th annual policy forum. I had the pleasure of speaking at the RETECH 2012 conference in October. I said then Read More >
